Europe currently remains an importance global center for the pharmaceutical industry with around €30bn of private sector R&D annual spending.Small and large firms work in an interconnected network with universities, hospitals and other partners. Although we have many of the foundations of success there are signs that Europe is losing competitiveness in some areas.
If Europe is to meet its future healthcare objectives and retain pharmaceutical innovation in the areas most valued by society, all sides need to build explicit strategies for managing financial sustainability now. This includes the need to improve the predictability of spend and the development of systems that ensure rational use of all medical technologies.
In this presentation, the speaker will depict the present challenges and put forward some ideas on how we can develop a more integrated approach that can help patients, the science community as well as the industry. He will suggest new ways to ensure Europe retains its leadership in life sciences research and fuel a thriving life sciences eco-system.